EP0566226A1 — Quinazoline derivatives
Assigned to AstraZeneca UK Ltd · Expires 1993-10-20 · 33y expired
What this patent protects
The invention concerns quinazoline derivatives of the formula I wherein m is 1, 2 or 3 and each R 1 includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)a …
USPTO Abstract
The invention concerns quinazoline derivatives of the formula I wherein m is 1, 2 or 3 and each R 1 includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)a lk anoyloxyamino, trifluor om ethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)al- kylenedioxy ; n is 1 or 2 and each R 2 includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof; processes for their preparation ; pharmaceutical compositions containing them ; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.